NAS10028,958S&P7,624−0.52%GOLD$4,008−1.29%BTC$80,785−0.36%VIX19.45+2.21%live tape · as of 02:03 UTC
The Screen · Healthcare · Drug Manufacturers - Specialty & Generic
Prestige Consumer Healthcare Inc.
PBH · the NYSE · USD · Market cap $2.3B · 890 employees
Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally.
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.33, read 2026-10-23
Ethical passes the values gate
Price47.92 USD
Fair value75.00
Ethical score70.0/100
Our investment reviews on this name
2026-10-11Read Markup45.26+5.9% to today ✓Distribution gives way to Markup after a 13% slide in 5 weeks
2026-09-09Read Distribution52.15-8.1% to today ✓Markup gives way to Distribution first Distribution read since July
2026-08-08Read Markup54.85-12.6% to today Distribution gives way to Markup after a 15% rise in 5 weeks
2026-07-02Read Distribution47.82+0.2% to today First review on file: Distribution
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Prestige Consumer Healthcare Inc. holds its Markup at $47.92. Consolidating, no directional conviction, held for 7 days.
As held on the ledger · 2026-10-21
Phase
Markup
Quantitative state
Consolidating, no directional conviction, held for 7 days
Price at the screen
$47.92
Valuation
13.42 trailing · 9.43 forward price to earnings
Values screen
PASS· score 70.0
Beta
0.34
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
29.92%
Below 33%
Interest-bearing debt is just 29.9% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
7.80%
Below 49%
Money owed to the company is 7.8% of assets, under the 49% limit.
Pass
Revenue purity
0.00%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Prestige Consumer Healthcare clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 30%, inside the ~33% line, and almost none of its income is interest, so it passes.
Read as at 2026-10-24. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when PBH's ethical verdict changes
Today PBH passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
Fair value range in USD, drawn from the 2026-10-21 screen. The gold marker is the market price at the same screen. A 56.5% margin of safety to the base estimate.
Third-party analyst targets: 5 covering, consensus None. The average target sits +46% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-21 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Everyday Remedies Trade Below Their Steady Value
Picture a bathroom cabinet full of familiar painkillers and cough treatments that sell year after year regardless of economic noise. Prestige Consumer Healthcare makes exactly those over-the-counter staples across North America and abroad, yet its revenue has slipped 5 percent while the shares sit at just 9.8 times forward earnings with a 17 percent profit margin and a clean ethical screen.
The valuation gap to our $75 fair value looks attractive on paper, and the 10 percent return on equity plus analyst median target of $70 hint at some support. Still, the opportunity rating stays at none because the business shows no clear growth driver or durable edge to close that gap quickly.
Revenue contraction and an unknown competitive position keep the setup fragile even at this price. Currency moves or retailer shifts could easily erode the apparent margin of safety further. Analysis, not advice.
The risks · The things to watch: as a drug manufacturers - specialty & generic name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
PBH trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-18Markup$49.20+8.7%Entry 8
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 8.7% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are down 43%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (5 analysts) rates it buy, with a mean price target of $67.
2026-10-11Markup · changed$45.26-3.3%Entry 7
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 3.3% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are down 43%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (5 analysts) rates it buy, with a mean price target of $67.
2026-10-02Distribution$46.80-10.3%Entry 6
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 10.3% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are down 43%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (5 analysts) rates it buy, with a mean price target of $67.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 4.9% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are down 43%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (5 analysts) rates it buy, with a mean price target of $67.
2026-08-08Markup · changed$54.85+14.7%Entry 4
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 14.7% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are down 43%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (5 analysts) rates it buy, with a mean price target of $67.
2026-07-18Distribution$47.82+0.0%Entry 3
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are down 43%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (5 analysts) rates it buy, with a mean price target of $67.
2026-07-03Distribution$47.82+0.0%Entry 2
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-02Distribution$47.82Entry 1
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
